Veena Charu, MD
Hematology-Oncology · Anaheim, CANPI 1568438976
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.7%. Reporting peaked in 2023 at $9,896 and has fallen 100.0% since, to $3 in 2025.
Across 489 payments — averaging $64.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$6K
- Pfizer$5K
- GSK$3K
- AstraZeneca$2K
- Bristol Myers Squibb$2K
- Gilead$2K
- plus $11K from 54 others
Across 169 payments — averaging $4808.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$227K
- Takeda Pharmaceuticals U.S.A., Inc.$157K
- Seagen Inc.$131K
- Amgen$85K
- Acerta Pharma LLC$73K
- Genentech, Inc.$34K
- plus $106K from 12 others
What the payments were for
- Consulting fees$17,77556%
- Speaking & faculty fees$1,0003%
- Travel & lodging$2,6338%
- Food & beverage$10,04232%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,560 in reported general payments places this provider in the 75th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 34 | $576,651 |
| VerzenioAbemaciclib | 36 | $534,406 |
| ErleadaApalutamide | 22 | $327,059 |
| JakafiRuxolitinib Phosphate | 20 | $313,845 |
| KeytrudaPembrolizumab | 19 | $261,490 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 15 | $250,004 |
| TagrissoOsimertinib Mesylate | 11 | $187,263 |
| Lupron DepotLeuprolide Acetate | 42 | $152,082 |
| ProliaDenosumab | 60 | $98,955 |
| XgevaDenosumab | 29 | $90,328 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $77,546 |
| ProcritEpoetin Alfa | 49 | $65,408 |
| ZarxioFilgrastim-Sndz | 41 | $58,986 |
| Abiraterone Acetate | 15 | $52,711 |
| EliquisApixaban | 52 | $34,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $2,212 | $576,65134 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $36 | $534,55558 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $681 | $410,93087 claims |
| Incyte CorporationJakafi | $572 | $313,84520 claims |
| MerckKeytruda | $267 | $261,49019 claims |
| AmgenProlia, Xgeva | $430 | $189,28389 claims |
| AstraZenecaTagrisso | $2,225 | $187,26311 claims |
| AbbVieLupron Depot | $94 | $152,08242 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $114 | $77,54611 claims |
| PfizerEliquis | $5,276 | $34,11452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in Anaheim
- Ajit ManiamAnaheim$10K
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.